Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
Authors:
- Loredana LorussoLLLoredana Lorusso
- Virginia CappagliVCVirginia Cappagli
- Laura ValerioLVLaura Valerio
- Carlotta GianiCGCarlotta Giani
- David ViolaDVDavid Viola
- Luciana PuleoLPLuciana Puleo
- Carla GambaleCGCarla Gambale
- Elisa MinaldiEMElisa Minaldi
- Maria Cristina CampopianoMCMaria Cristina Campopiano
- Antonio MatroneAMAntonio Matrone
- Valeria BotticiVBValeria Bottici
- Laura AgateLALaura Agate
Open Access
- 18 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 3117
Abstract
Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy of the targeted therapies and, in particular, tyrosine kinase inhibitors (TKIs) has been demonstrated. They can prolong the disease progression-free survival and represent the most important therapeutic option for the treatment of advanced and progressive thyroid cancer. Currently, lenvatinib and sorafenib are the approved drugs for the treatment of RAI-refractory DTC and PDTC while advanced MTC can be treated with either cabozantinib or vandetanib. Dabrafenib plus trametinib is the only approved treatment by FDA for BRAFV600E mutated ATC. A new generation of TKIs, specifically for single altered oncogenes, is under evaluation in phase 2 and 3 clinical trials. The aim of this review was to provide an overview of the current and future treatments of thyroid cancer with regards to the advanced and progressive cases that require systemic therapies that are becoming more and more targeted on the molecular identity of the tumor.Keywords
Funding Information
- Associazione Italiana Ricerca sul Cancro (Grant 2018, Project code 21790)
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017, protocol 2017YTWKWH)
This publication has 142 references indexed in Scilit:
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationJournal of Clinical Investigation, 2011
- Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK GeneCancer Research, 2011
- Rearrangements of NTRK1 gene in papillary thyroid carcinomaMolecular and Cellular Endocrinology, 2010
- 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 studyThyroid Research, 2009
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1Cancer Research, 2009
- A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with OutcomeThyroid®, 2009
- Dysregulation of the Phosphatidylinositol 3-Kinase Pathway in Thyroid NeoplasiaEndocrinology and Metabolism Clinics of North America, 2008
- The Prevalence and Prognostic Value of BRAF Mutation in Thyroid CancerAnnals of Surgery, 2007